

**u<sup>b</sup>**

## Flexible generic framework for evidence synthesis in health technology assessment using network meta-analysis

Presented by: Tasnim Hamza

Authors: Tasnim Hamza, Fabio Pellegrini, Jens Kuhle, Pascal Benkert, Suvitha Subramaniam, Sabine Schaedelin, Cynthia Iglesias, Andrea Manca, Konstantina Chalkou, Georgia Salanti

42<sup>nd</sup> Annual Conference of the International Society for Clinical Biostatistics (ISCB) 18-22 July 2021

1

1

**u<sup>b</sup>**

- IPD**
  - Lengthy process, increased costs
  - Accessibility to include IPD from all trials
  - Overcome the AD shortcomings
  - gold standard
  - Standardize the analysis
- AD**
  - Data is accessible in the published literature
  - Heterogeneity across trials
  - MR on aggregate information
  - Ecological bias
- RCT**
  - Idealized settings
  - Restricted inclusion criteria
  - Limit: generalizability
  - 'Low' Bias
  - Most reliable
- NRS**
  - More available
  - Reflect the reality
  - Bias
  - Confounders are not addressed
  - Concern about transitivity and consistency

2

2

**u<sup>b</sup>**

- Three level hierarchical model
- naive
- Bias adjustment 1
- Bias adjustment 2
- Use NRS as a prior

3

3

**u<sup>b</sup>**

**Cross NMA model**

- Three level hierarchical model
- naive
- Bias adjustment 1
- Bias adjustment 2
- Use NRS as a prior

4

4

**u<sup>b</sup>**

### Cross NMR model naive

Treatment effect in study j:  $\delta_j$

AD RCT and NRS

For j study with k treatment

$$r_{jk} \sim \text{Bin}(p_{jk}, n_{jk})$$

$$\text{logit}(p_{jk}) = u_{jb} + \beta_{2,bk}^B x_j + \delta_{jbk}$$

IPD RCT and NRS

For i individual in j study with k treatment

$$y_{ijk} \sim \text{Bernoulli}(p_{ijk})$$

$$\text{logit}(p_{ijk}) = u_{jb} + \beta_{1j} x_{ij} + \beta_{2,bk}^W (x_{ij} - x_j) + \beta_{2,bk}^B x_j + \delta_{jbk}$$

5

5

**u<sup>b</sup>**

### Cross NMR model naive

Treatment effect in study j:  $\delta_j$

Combine AD and IPD

$$\delta_{jbk} \sim N(d_{Ak} - d_{Ab}, \tau^2)$$







$$\beta_{2,bk}^B \sim N(B_{Ak}^B - B_{Ab}^B, \sigma_B^2)$$


$$\beta_{2,bk}^W \sim N(B_{Ak}^W - B_{Ab}^W, \sigma_W^2)$$

$$u_{jb}, \beta_{1j} \sim N(0, 10^2)$$


6

6






13



14



15

### crosnma library

**crosnma to synthesize cross-design evidence and cross-format data using network meta-analysis**

Basim Hanna and George Salanti

2021-06-23

- 1. Introduction
- 2. The synthesis models
  - 2.1. Naive synthesis
  - 2.2. Using non-randomized studies (NRS) as a prior
  - 2.2.1. Bias-adjusted model 1
  - 2.2.2. Bias-adjusted model 2
  - 2.2.3. Assumptions about the model parameters
- 3. Synthesis of studies comparing drugs for relapsing-remitting multiple sclerosis
  - 3.1. Identification of the data
    - 3.1.1. Naive network meta-analysis
    - 3.1.2. Naive network meta-regression
    - 3.1.3. Using non-randomized studies as a prior in network meta-regression
  - 3.2. Analysis
    - 3.2.1. Bias-adjusted model 1
    - 3.2.2. Bias-adjusted model 2
- 4. References

```
library(crosnma)
library(rjags)
fit <- crosnma("crosnma.Rproj", code = "code", data = "data", n.iter = 10000, n.burn = 1000, n.thin = 10, n.save = 1000, n.load = 1000, n.load.save = 1000)
fit <- modeler::load(fit)
```

**1 Introduction**


16

### Case study


- Relapsing remitting multiple sclerosis (RRMS)
- Binary outcome: relapse in 2 years (0/1)
- Covariate: age

Study	Type of data	Treatment compared	Design/RoB	Probability of risk	Sample size
DEFINE	IPD	Dimethyl fumarate Placebo	RCT/high risk	Beta(3,1)	1234
CONFIRM	IPD	Dimethyl fumarate Glatiramer acetate Placebo	RCT/high risk	Beta(3,1)	1417
AFFIRM	IPD	Natalizumab Placebo	RCT/low risk	Beta(1,20)	939
Bornstein	AD	Glatiramer acetate Placebo	RCT/high risk	Beta(3,1)	50
Johnson	AD	Glatiramer acetate Placebo	RCT/unclear risk	Beta(1,1)	251
Swiss cohort	IPD	All/placebo	NRS/high risk	Beta(30,1)	290


17



18



19



20

### Summary

- Introduce 4 cross NMA/NMR framework approaches
- All models are implemented in a new R package: **crossnma**
- Apply the models on a network of drugs about RRMS
- We have to acknowledge the differences between RCT and NRS
- The models need to be investigated further in larger network

21

### References

- Dias, Sofia, N. J. Welton, V. C. C. Marinho, G. Salanti, J.P.T Higgins, and A. E. Ades. 2010. "Estimation and Adjustment of Bias in Randomized Evidence by Using Mixed Treatment Comparison Meta-Analysis." *Journal of the Royal Statistical Society* 173: 613–29.
- Verde, Pablo Emilio. 2020. "A Bias-Corrected Meta-Analysis Model for Combining, Studies of Different Types and Quality." *Biometrical Journal. Biometrische Zeitschrift*, September. <https://doi.org/10.1002/bimj.201900376>.
- Efthimiou O, Mavridis D, Debray TP, Samara M, Belger M, Siontis GC, Leucht S, Salanti G; GetReal Work Package 4. Combining randomized and non-randomized evidence in network meta-analysis. *Stat Med*. 2017 Apr 15;36(8):1210-1226. doi: 10.1002/sim.7223.

22

For questions/comments, please contact me at [tasnim.hamza@ispm.unibe.ch](mailto:tasnim.hamza@ispm.unibe.ch)

23